These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 26567318)

  • 1. Drug sensitivity testing platforms for gastric cancer diagnostics.
    Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
    J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
    Joo MK; Park JJ; Chun HJ
    World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Companion diagnostics for the targeted therapy of gastric cancer.
    Yoo C; Park YS
    World J Gastroenterol; 2015 Oct; 21(39):10948-55. PubMed ID: 26494953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized medicine in gastric cancer: Where are we and where are we going?
    Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
    World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNAs as potential biomarkers in gastric cancer: Opportunities and challenges.
    Yang Z; Guo X; Li G; Shi Y; Li L
    Cancer Lett; 2016 Feb; 371(1):62-70. PubMed ID: 26577810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine.
    Wang S; Yuan L
    Biosci Trends; 2016 Jul; 10(3):171-80. PubMed ID: 27251446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalising the treatment of prostate cancer.
    Gunjur A
    Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
    [No Abstract]   [Full Text] [Related]  

  • 9. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients.
    Kagawa S; Shigeyasu K; Ishida M; Watanabe M; Tazawa H; Nagasaka T; Shirakawa Y; Fujiwara T
    World J Gastroenterol; 2014 Dec; 20(47):17796-803. PubMed ID: 25548478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 13. Precision and predictive medicine in urothelial cancer: are we making progress?
    Bellmunt J; Orsola A; Sonpavde G
    Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
    Molloy MP; Engel A
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
    [No Abstract]   [Full Text] [Related]  

  • 15. Lack of access to targeted cancer therapy.
    Burki TK
    Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211
    [No Abstract]   [Full Text] [Related]  

  • 16. Incorporating Tumor Genomic Profiling and Circulating Tumor Cell-derived Organoids into Clinical Practice for Gastrointestinal Cancers.
    Wu WC; Hsu CF; Chen MH; Chen SC; Hung YP; Chiang NJ
    Anticancer Res; 2024 Aug; 44(8):3481-3491. PubMed ID: 39060051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention.
    Bernardi MP; Ngan SY; Michael M; Lynch AC; Heriot AG; Ramsay RG; Phillips WA
    Lancet Oncol; 2015 Dec; 16(16):e611-21. PubMed ID: 26678214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation-mediated gene silencing as biomarkers of gastric cancer: a review.
    Nakamura J; Tanaka T; Kitajima Y; Noshiro H; Miyazaki K
    World J Gastroenterol; 2014 Sep; 20(34):11991-2006. PubMed ID: 25232236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer.
    Jia S; Cai J
    Anticancer Res; 2016 Mar; 36(3):1111-8. PubMed ID: 26977006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer.
    Zhao Y; Li S; Zhu L; Huang M; Xie Y; Song X; Chen Z; Lau HC; Sung JJ; Xu L; Yu J; Li X
    Cell Rep Med; 2024 Jul; 5(7):101627. PubMed ID: 38964315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.